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Summary
 
Leukocyte migration into sites of inflammation involves multiple molecular interactions be-
tween leukocytes and vascular endothelial cells, mediating sequential leukocyte capture, roll-
ing, and firm adhesion. In this study, we tested the role of molecular interactions between frac-
talkine (FKN), a transmembrane mucin-chemokine hybrid molecule expressed on activated
endothelium, and its receptor (CX
 
3
 
CR1) in leukocyte capture, firm adhesion, and activation
under physiologic flow conditions. Immobilized FKN fusion proteins captured resting peripheral
blood mononuclear cells at physiologic wall shear stresses and induced firm adhesion of resting
monocytes, resting and interleukin (IL)-2–activated CD8
 
1
 
 T lymphocytes and IL-2–activated
NK cells. FKN also induced cell shape change in firmly adherent monocytes and IL-2–acti-
vated lymphocytes. CX
 
3
 
CR1-transfected K562 cells, but not control K562 cells, firmly adhered
to FKN-expressing ECV-304 cells (ECV-FKN) and tumor necrosis factor 
 
a
 
–activated human
umbilical vein endothelial cells. This firm adhesion was not inhibited by pertussis toxin,
EDTA/EGTA, or antiintegrin antibodies, indicating that the firm adhesion was integrin inde-
pendent. In summary, FKN mediated the rapid capture, integrin-independent firm adhesion,
and activation of circulating leukocytes under flow. Thus, FKN and CX
 
3
 
CR1 mediate a novel
pathway for leukocyte trafficking.
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T
 
he recruitment of leukocytes from the circulation into
sites of inflammation is a dynamic process involving
multiple regulated steps (1, 2). The initial step involves
leukocyte contact and rolling on endothelium, and is pre-
dominantly mediated by the selectins (3, 4). Subsequently,
activation through pertussis toxin (PTX)
 
1
 
-sensitive G pro-
tein–coupled receptors leads to upregulation of integrin
adhesiveness and activation-dependent stable arrest (5–7).
Chemokines are soluble, cell-selective molecules that reg-
ulate the activation step of leukocyte migration (5–7).
Fractalkine (FKN) is a unique, transmembrane, mucin/
chemokine hybrid molecule expressed on the cell surface
of IL-1– and TNF-activated endothelium (8). FKN shares
high homology with the CC family of chemokines, but has
an insert of three amino acids between the two NH
 
2
 
-ter-
minal cysteine residues, conferring a CX
 
3
 
C structural motif
(8). In vitro
 
, 
 
FKN has been shown to have multiple activi-
ties including signal transduction through the PTX-sensi-
tive G protein–coupled receptor CX
 
3
 
CR1 (also called
V28) (9) and adhesion of monocytes, NK cells, and T cells
in static binding assays (8, 9). In addition, the soluble form
of FKN is chemotactic for monocytes, NK cells, and T
lymphocytes (8–10). FKN’s unique structure and multi-
plicity of molecular activities led us to hypothesize that it
may regulate several pathways involved in leukocyte mi-
gration.
Here, we report that FKN on endothelium interacting
with CX
 
3
 
CR1 on leukocytes can mediate the initial cap-
ture, firm adhesion, and activation of circulating leuko-
 
1
 
Abbreviations used in this paper:
 
 ELC, EBI1 ligand chemokine; FKN, frac-
talkine; HUVECs, human umbilical vein endothelial cells; IF, immuno-
fluorescence; MCP, monocyte chemotactic protein; PTX, pertussis toxin;
SEAP, secreted placental alkaline phosphatase; TARC, thymus and acti-
vation regulated chemokine.
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cytes. Thus, we describe a new pathway for leukocyte mi-
gration.
 
Materials and Methods
 
Cells, Transfections, and Culture Conditions.
 
Resting PBMCs
were isolated from whole blood by centrifugation over lympho-
cyte separation medium (Organon Teknika, Durham, NC) as de-
scribed previously (11). IL-2–activated PBLs were generated by
culturing PBMCs in RPMI containing 10% FBS and 400 U/ml
IL-2 (R & D Systems, Inc., Minneapolis, MN) for 5 d as de-
scribed previously (9) and harvesting the nonadherent cells.
Human umbilical vein endothelial cells (HUVECs) were ob-
tained from Clonetics Corp. (San Diego, CA), and grown in
EGM
 
Ô
 
 medium (Clonetics Corp.). ECV-304 cells were ob-
tained from the American Type Culture Collection (Rockville,
MD) and the generation of FKN-expressing ECV-304 cells
(ECV-FKN) has been described previously (9). ECV-304 and
ECV-FKN cells were maintained in M199 medium (GIBCO
BRL, Gaithersburg, MD) supplemented with 10% FBS. K562
cells were obtained from the American Type Culture Collection
and maintained in RPMI supplemented with 10% FBS. Cells
were grown to confluence on 25-mm glass coverslips before use
in flow assays. HUVECs used in flow assays were activated with
TNF-
 
a
 
 (100 ng/ml; R & D Systems, Inc.) for 12 h.
For stable transfection of CX
 
3
 
CR1 in K562 cells, the expression
plasmid pCAGGS-Neo-V28 was transfected into K562 cells as
described previously (9). Control neomycin-expressing cells were
generated by transfecting pcDNA3.1
 
2
 
 (Invitrogen, Carlsbad, CA)
into K562 cells. After selection with 500 
 
m
 
g/ml G418 for 3 wk,
drug resistant cells were used unselected. Expression of CX
 
3
 
CR1
was assessed by RNAse protection using the hCKR-5 and hCKR-6
probe sets (PharMingen, San Diego, CA) as described by the
manufacturer. CX
 
3
 
CR1 is identical to V28 in the probe set.
K562 cells expressed no mRNA for chemokine receptors CCR1,
CCR2, CCR3, CCR4, CCR5, CCR7, CCR8, CXCR1,
CXCR2, CXCR3, CXCR4, and CX
 
3
 
CR1. Cell surface expres-
sion of CX
 
3
 
CR1 was also tested by indirect immunofluorescence
(IF) as described below. To inhibit signal transduction through
CX
 
3
 
CR1, cells were treated with PTX at 500 ng/ml for 30 min
at 37
 
8
 
C. To inhibit integrin function, cells were preincubated
with 5 mM each of EDTA and EGTA in flow buffer (see below)
for 15 min before use in flow assays, and both EDTA and EGTA
were added to the flow buffer. Integrins were also blocked by
preincubation of K562-neo or K562-CX
 
3
 
CR1 cells for 10 min
with the anti-
 
b
 
1 antibody 4B4 (anti-CD29, IgG1) (12) or the
anti-
 
b
 
2 antibody H52 (anti-CD18, IgG1) (13) before use in flow
assays. Antiintegrin antibodies were used as ascites fluid diluted
1:100.
 
Recombinant Proteins.
 
FKN, thymus and activation regulated
chemokine (TARC), and EBI1 ligand chemokine (ELC) fused with
secreted placental alkaline phosphatase (FKN-SEAP, TARC-
SEAP, and ELC-SEAP), and a control SEAP protein were pro-
duced as described previously (9, 14, 15). Monocyte chemotactic
protein (MCP)-1–SEAP was also produced essentially as described
previously (14). In brief, the DNA fragment containing the coding
region of MCP-1 was amplified from MCP-1 cDNA by PCR. Af-
ter digestion with SalI and XbaI, the MCP-1 fragment was sub-
cloned into SalI–XbaI sites of pDREF-SEAP(His)
 
6
 
-Hyg vector in
order to express MCP-1 as a soluble fusion protein linked through
five amino acid residues (Ser-Arg-Ser-Ser-Gly) with SEAP tagged
with six histidine residues [(His)
 
6
 
]. 293/EBNA-1 cells (Invitro-
gen) were transfected with the expression vector pDREF–MCP-
1–SEAP(His)
 
6
 
 using lipofectamine (GIBCO BRL). The transfected
cells were incubated for 3–4 d in DMEM supplemented with 10%
FBS. The supernatant containing each SEAP(His)
 
6
 
 chimera was col-
lected by centrifugation, filtered (0.45 
 
m
 
m), and stored at 4
 
8
 
C after
adding 20 mM Hepes (pH 7.4) and 0.02% sodium azide. 25-mm
round glass coverslips were coated with fusion proteins as described
previously (9). In brief, 10 
 
m
 
g/ml anti-SEAP antibody 8B6 (Sigma
Chemical Co., St. Louis, MO) in buffer (50 mM Tris, pH 9.5) was
placed on the coverslip and incubated overnight at 4
 
8
 
C. The cov-
erslips were blocked in PBS with 1% BSA at room temperature for
2 h. After washing, 10 nM FKN-SEAP, SEAP, MCP-1–SEAP,
TARC-SEAP, or ELC-SEAP was added and incubated at room
temperature for 1 h. Coverslips were washed three times before use
in the flow chamber.
 
Hydrodynamic In Vitro Flow Chamber Experiments.
 
Parallel plate
flow chamber assays were performed as described previously (16).
In brief, protein-coated glass coverslips were assembled in a paral-
lel plate laminar flow chamber and placed on the stage of an in-
verted phase-contrast microscope. K562-neo or K562-CX
 
3
 
CR1
cells were suspended at a density of 10
 
6
 
 cells/ml in flow buffer
(PBS containing 0.75 mM CaCl
 
2
 
, 0.75 mM MgCl
 
2
 
, and 0.5%
bovine serum albumin). Cell suspensions were perfused through
the chamber for a 5- or 10-min period at a wall shear stress of
0.25 dynes/cm
 
2
 
 via a syringe pump (Harvard Apparatus, South
Natick, MA). At the end of the 5- or 10-min perfusion period,
flow buffer was perfused through the chamber at 1.85 dynes/cm
 
2
 
for 3 min and at 10 dynes/cm
 
2
 
 for 3 min, and multiple 
 
3
 
100
fields were visualized. The entire experiment was recorded using
a CCD video camera (Hitachi Denshi, Ltd., Woodbury, NY) and
a Sony SuperVHS video recorder (Sony Electronics, Inc., San
Jose, CA). For some experiments, cell suspensions were initially
passed through the chamber at a low shear stress (0.25 or 0.5
dynes/cm
 
2
 
), followed by flow buffer at progressively increasing
wall shear stresses of 0.5, 1.0, 1.85, 5.0, 10, and 20 dynes/cm
 
2
 
 at
2-min intervals to determine the stability of adhesive interactions.
The number of adherent cells was determined by analyzing the
videotapes and counting 16 fields each with a 0.16-mm
 
2
 
 area.
 
Immunophenotypic Analysis.
 
PBMCs and IL-2–activated PBLs
were characterized by three-color flow cytometry as described pre-
viously (17) on a FACStarPlus
 
Ò
 
 (Becton Dickinson, San Jose, CA)
using CD3-FITC, CD4-PE, CD8-Cy5, CD14-PE, CD16/56-PE,
and CD19-FITC directly conjugated antibodies generously pro-
vided by Coulter Corp. (Hialeah, FL). Resting PBMCs and IL-2–
activated PBLs that bound to FKN-SEAP–coated coverslips were
characterized by two-color IF using CD3-FITC, CD4-PE, CD8-
FITC, CD14-PE, CD16/56-PE, and CD19-FITC antibodies. In
brief, coverslips were incubated with 50 
 
m
 
l of mAbs diluted in PBS
with 1% BSA for 15 min at room temperature and washed. Cover-
slips were mounted on glass slides and analyzed by IF on an epiflu-
orescent microscope.
Cell surface expression of FKN was assessed by indirect IF us-
ing mAb 1D6 to the mucin domain of FKN as described previ-
ously (9). Expression of FKN on HUVECs was determined by
two-color flow cytometry using mAb 1D6 and directly conju-
gated CD31-PE mAb kindly provided by Coulter Corp. (Hi-
aleah, FL) as described previously (17). Cell surface expression of
CX
 
3
 
CR1 was also determined by indirect IF. In brief, 10
 
6
 
 cells
were incubated with 5 nM chemokine-SEAP fusion proteins in
PBS containing 0.05% NaN
 
3
 
 for 30 min at room temperature and
washed. After incubation with anti–alkaline phosphatase mAb
8B6 and washing, cells were incubated with fluorescein-conju-
gated goat anti–mouse Ig (Cappell, Gaithersburg, MD), washed,
and analyzed by flow cytometry. 
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Results
 
FKN Mediates Leukocyte Capture.
 
To determine whether
FKN can mediate capture of free flowing leukocytes under
conditions of shear stress encountered in vivo, freshly iso-
lated PBMCs were perfused over immobilized FKN-SEAP
fusion proteins at physiologic shear stresses. FKN-SEAP
(but not SEAP alone) captured leukocytes at wall shear
stresses up to 1.85 dynes/cm
 
2
 
 (Fig. 1). The capture of leu-
kocytes by FKN was rapid (
 
,
 
33 ms), and no rolling was
observed. Despite diminished efficiency of capture with in-
creasing wall shear stress, there was no significant difference
in the rate of capture of monocytes compared with lym-
phocytes. Thus, FKN-mediated leukocyte capture at phys-
iologic wall shear stresses.
 
PBMCs and IL-2–Activated PBLs Firmly Adhere to and Are
Activated by FKN.
 
To test if FKN could support the firm
adhesion of normal human leukocytes, both resting PBMCs
and IL-2–stimulated PBLs were perfused over immobilized
SEAP fusion proteins at 0.25 dynes/cm
 
2
 
 and allowed to
capture for 5 min. Firm adhesion was defined as the ability
of cells to resist detachment at a wall shear stress of 10
dynes/cm
 
2
 
. TARC-SEAP and ELC-SEAP were used as
controls. CCR4, the receptor for TARC, is selectively ex-
pressed on CD4
 
1
 
 T cells (14) and CCR7, the receptor for
ELC/MIP-3
 
b
 
, is selectively expressed on activated T and
B cells (15, 18, 19). Although resting PBMCs and IL-2–
stimulated PBLs adhered firmly to purified FKN-SEAP
(Fig. 2 
 
B
 
), they were neither captured by (data not shown)
nor adherent to (Fig. 2 
 
B
 
) control proteins. Virtually all
captured cells remained firmly adherent throughout the ex-
periments (
 
.
 
10 min in duration). As determined by IF, the
majority of firmly bound PBMCs were either CD14
 
1
 
monocytes (62.5%) or CD8
 
1
 
 T cells (30%; Fig. 2 
 
C
 
). Rest-
ing NK cells bound to immobilized FKN, but the percent-
age of bound NK cells varied widely between experiments
(2.5–15%). Of the IL-2–activated PBLs bound to FKN,
37.5% were NK cells (CD16
 
1
 
 and/or CD56
 
1
 
), 56.3% were
CD8
 
1
 
 T cells, and only 6.3% were CD4
 
1
 
 T cells. Thus,
FKN mediated the firm adhesion of resting monocytes, rest-
Figure 1. PBMCs are cap-
tured by immobilized FKN-
SEAP under physiologic wall
shear stresses. Freshly isolated
PBMCs were perfused over im-
mobilized FKN-SEAP and SEAP
fusion proteins at wall shear
stresses of 0.25, 0.5, 1, or 1.85
dynes/cm2 for 5 min. After per-
fusing the chamber with flow
buffer at 10 dynes/cm2 for 3
min, the number of adherent
cells was determined. Also shown
are the numbers of PBMCs cap-
tured by FKN-SEAP (d), mono-
cytes captured by FKN-SEAP (s), lymphocytes captured by FKN-SEAP
(h) and PBMCs captured by control SEAP fusion protein (j). The error
bars represent the mean 6 SD of the number of cells bound. Data are
representative of three independent experiments.
Figure 2. Resting monocytes, resting and IL-2–activated CD81 T
cells, and IL-2–activated NK cells firmly adhere to FKN under flow. Im-
mobilized FKN was tested for its ability to capture and induce the firm
adhesion of freshly isolated PBMCs in the parallel plate flow chamber.
Cells were perfused over immobilized proteins at 0.25 dynes/cm2 for 5
min and washed at 10 dynes/cm2. Resting PBMCs and IL-2–activated
PBLs were characterized by three-color flow cytometry and firmly adher-
ent cells were characterized by two-color IF microscopy. (A) Photomi-
crographs of PBMCs and IL-2–activated PBLs bound to immobilized
SEAP and FKN-SEAP. (B) Numbers of PBMCs and IL-2–activated PBLs
remaining bound to immobilized SEAP, FKN-SEAP, TARC-SEAP, and
ELC-SEAP at 10 dynes/cm2. (C) Percentages of leukocyte cell types
binding to FKN-SEAP under flow. The cell types measured and quanti-
fied were: CD141 monocytes, CD31CD16/562 T cells, CD31CD41 T
cells, CD31CD81 T cells, and CD16/561 NK cells. The percentage of
leukocyte subsets in the starting material as measured by multicolor flow
cytometry is depicted by white bars, and the percentage of cell subsets in
the FKN-bound fraction as measured by two-color IF microscopy is de-
picted by black bars. Leukocyte subsets from both resting PBMCs and
IL-2 activated PBLs bound firmly and specifically to FKN-SEAP under
flow. FKN preferentially bound resting monocytes, resting and IL-2–acti-
vated CD81 T cells, and IL-2–activated NK cells. The majority of FKN-
bound, IL-2–activated PBLs formed pseudopods. Data are representative
of three experiments performed. The error bars represent the mean 6 SD
of the number of cells bound. 
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ing and activated CD8
 
1
 
 T cells, and resting and activated
CD16/56
 
1
 
 NK cells under physiologic flow conditions.
Soluble FKN-SEAP fusion proteins bind to and trans-
duce signals through CX
 
3
 
CR1 to mediate a Ca
 
21 flux and
chemotaxis (9). Immobilized FKN induced the spreading
of bound monocytes (Fig. 2 A), but had no effect on the
shape of resting PBLs. Furthermore, FKN induced pseudo-
pod formation in the majority of IL-2–activated PBLs.
Thus, FKN can activate resting monocytes and IL-2–acti-
vated PBLs.
CX3CR1 Is the Leukocyte Receptor for FKN-mediated Cap-
ture and Firm Adhesion. Normally, CX3CR1 mRNA is ex-
pressed primarily by CD161 NK cells and at low levels by
CD81 T cells and CD141 monocytes (9). As for other
chemokine receptors, IL-2 enhances CX3CR1 expression on
both CD41 and CD81 T cells (9). Since these were the very
cell types that were captured by and firmly adherent to pu-
rified FKN before becoming activated, FKN-CX3CR1 in-
teractions probably mediated these events. Thus, the ability
of FKN-transfected ECV-304 transformed endothelial cells
(ECV-FKN; Fig. 3) to capture and induce stable arrest of
CX3CR1-transfected K562 erythroleukemia cells (K562-
CX3CR1; Fig. 3) was examined. CX3CR1-transfected and
control cells were allowed to bind to ECV-FKN cells at
0.25 dynes/cm2 for 10 min and exposed to increasing shear
stresses up to 20 dynes/cm2 (Fig. 4 A). K562-CX3CR1 cells
remained bound to ECV-FKN monolayers at wall shear
stresses up to 10 dynes/cm2, and began to release at 20 dynes/
cm2. Thus, FKN on endothelium interacts with CX3CR1
on leukocytes to mediate their capture and firm adhesion.
Figure 3. Expression of FKN in ECV-304 cells and CX3CR1 in K562
cells. The top shows histograms depicting the binding of anti-FKN mAb
1D6 (solid lines) and control mAb P3 (dashed lines) to untransfected
ECV-304 cells and to transfected ECV-FKN cells. The bottom shows
histograms depicting the binding of FKN-SEAP (solid lines) and MCP-1–
SEAP (dashed lines) to control K562-neo cells and transfected K562-
CX3CR1 cells.
FKN-mediated Firm Adhesion Is Integrin Independent. To
test the role of integrins and signal transduction through
CX3CR1, the effect of PTX, EDTA/EGTA, and antiin-
tegrin antibodies on FKN-mediated firm adhesion was
tested. Neither PTX (known to inhibit Ca21 mobilization
and chemotaxis in CX3CR1 expressing cells; 9) nor EDTA/
EGTA (to disrupt integrin function; 20, 21) had an effect
on FKN-mediated capture or firm adhesion (Fig. 4 A).
Function-blocking antiintegrin mAbs to b1 (4B4; 12) and
b2 (H52; 13) subunits also had no effect on the firm adhe-
sion of K562-CX3CR1 cells to ECV-FKN cells under flow
(Fig. 4 B). Therefore, FKN-mediated capture and firm ad-
hesion occurred independently of integrin activation and
PTX-sensitive signal transduction through CX3CR1.
To further confirm the specificity of FKN-CX3CR1–
mediated adhesive interactions, the ability of immobilized
FKN-SEAP to induce the firm adhesion of CX3CR1-
expressing versus nonexpressing cells was compared. FKN-
SEAP, but not SEAP or MCP-1–SEAP, could support firm
adhesion of K562-CX3CR1 under physiologic wall shear
stresses (Fig. 4 C). Thus, FKN–CX3CR1 interactions alone
are sufficient to mediate firm adhesion under flow.
TNF-a–activated HUVECs Support FKN-mediated Leuko-
cyte Arrest. Although the above studies indicate that FKN
can support firm adhesion of leukocytes under conditions
of flow, they were performed with either purified fusion
proteins or with transfected cells. To determine whether
the FKN interaction is physiologically relevant, the level of
FKN expression on TNF-activated primary HUVECs was
tested. TNF-a induced the expression of FKN on the sur-
face of a subset of CD311 HUVECs (Fig. 5, A and B).
FKN expression was induced by 1 h, and was maximal by
6–12 h, in a dose-dependent manner with peak expression
at a dose of 100 ng/ml TNF-a (data not shown). Subsets of
TNF-activated HUVECs and ECV-FKN cells expressed
similar levels of FKN (Fig. 5 C), indicating that ECV-FKN
cells express physiologically relevant levels of FKN. To fur-
ther confirm this point, the ability of TNF-activated HU-
VECs to induce stable arrest of K562-CX3CR1 cells was
tested. CX3CR1-transfected and control cells were allowed
to bind to resting and TNF-activated HUVECs at 0.5
dynes/cm2 for 5 min and were exposed to increasing shear
stresses up to 20 dynes/cm2 (Fig. 5, D and E). K562-
CX3CR1 cells did not bind to unactivated HUVECs (Fig.
5 D), but did bind to a subset of TNF-activated HUVECs
(data not shown). Although some K562-CX3CR1 cells be-
gan to release from TNF-activated HUVECs at a shear
stress of 5 dynes/cm2, a subset of cells remained bound at
wall shear stresses up to 20 dynes/cm2 (Fig. 5 E). Thus,
HUVECs can be induced to express sufficient levels of
FKN to mediate leukocyte stable arrest.
Discussion
In the current models of leukocyte migration, chemo-
kines and their receptors transduce signals to the rolling leu-
kocyte to induce cell arrest and firm adhesion by activating1417 Fong et al.
the adhesive capacity of integrins (1, 2, 5–7). This study
demonstrates new roles for chemokines and their receptors
in leukocyte migration, and describes a novel mechanism
of leukocyte capture, firm adhesion, and activation medi-
ated by the interactions of FKN with CX3CR1.
We have shown that FKN alone on the endothelium can
mediate leukocyte capture and firm adhesion of mono-
cytes, CD81 T cells, and CD16/561 NK cells. Although
CX3CR1 mRNA is also expressed by IL-2 activated CD41
T cells (9), they did not firmly adhere to immobilized FKN
in these studies. The reason for this is not clear. Although
CX3CR1 on the leukocyte can serve as the receptor for
FKN to mediate all of these functions, FKN may also inter-
act with other receptors. In the current models of leuko-
cyte recruitment, selectins capture circulating leukocytes in
the primary adhesion step (1–4). The selectins recognize
distinct, but closely related, sialylated carbohydrates on
their receptors (22–25). For example, L-selectin recognizes
mucin-like molecules with extensive O-glycosylation (22–
26). Since FKN has a mucin-like domain with many po-
tential O-glycosylation sites, it may interact with selectins.
However, in this study, selectins were not necessary for
FKN-CX3CR1 adhesion since K562 cells do not express
detectable levels of L-, E-, or P-selectin (27 and data not
shown). Thus, in this system, leukocyte capture by FKN
was selectin independent.
Leukocyte firm adhesion, in the multistep model of leu-
kocyte migration, requires activation by chemokines and is
mediated primarily by the integrin family of adhesion mol-
ecules and their receptors (1, 2). In this study, FKN inter-
actions with CX3CR1 were sufficiently strong to mediate
firm adhesion under conditions of high wall shear stresses
(up to 20 dynes/cm2), without the involvement of in-
tegrins or other adhesion molecules. Combined with the
ability of FKN to capture free-flowing leukocytes at physi-
ologic wall shear stresses (1.85 dynes/cm2), this indicates
that FKN and CX3CR1 mediate leukocyte capture and
firm adhesion under flow. However, FKN and CX3CR1
may also act in concert with other effectors of the classical
multistep pathways of leukocyte migration.
FKN appears to be unique amongst the chemokines in
its ability to induce leukocyte firm adhesion. Neither
TARC nor ELC fusion proteins were able to induce the
firm adhesion of flowing PBMC. FKN naturally has a mu-
cin stalk, whereas the other chemokines do not. The nega-
tive results with TARC and ELC may have been due to
the fact that they lack mucin stalks. The extension provided
by the mucin stalk may be a key factor in allowing FKN to
mediate firm adhesion.
FKN expression is induced on primary cultures of hu-
man umbilical vein and pulmonary artery endothelium by
the proinflammatory cytokines IL-1 and TNF-a (8, 10).
Figure 4. Integrin-independent firm adhesion of K562-CX3CR1
cells to ECV-FKN cells and immobilized FKN-SEAP under physiologic
flow conditions. (A) K562-CX3CR1 cells remain firmly adherent to
ECV-FKN cells under physiologic wall shear stresses, and this FKN-
mediated firm adhesion is PTX insensitive and integrin independent.
K562-neo cells and K562-CX3CR1 cells (6 EDTA/EGTA and 6
PTX treatment) were perfused over ECV-FKN monolayers for 10 min
at 0.25 dynes/cm2 and subjected to increasing wall shear stresses up to
20 dynes/cm2. Shown are the numbers of firmly adherent cells at vari-
ous shear stresses. (B) Anti-b1 and b2 integrin mAbs have no effect on
the firm adhesion of K562-CX3CR1 cells to ECV-FKN cells. The
numbers of adherent K562-neo and K562-CX3CR1 cells at 1.85 dynes/
cm2 and 10 dynes/cm2 in the absence and presence of anti-b1 and b2
integrin mAbs are shown. (C) K562-CX3CR1 cells bind to immobi-
lized FKN under flow. FKN-SEAP, MCP-1–SEAP, and SEAP fusion
proteins were immobilized by binding to glass coverslips coated with
anti–alkaline phosphatase mAbs and were tested for their ability to sup-
port firm adhesion of K562-CX3CR1 cells under flow. Cells were per-
fused over immobilized SEAP fusion proteins for 10 min at 0.25 dynes/
cm2, and exposed to a wall shear stress of 10 dynes/cm2. Shown are the
numbers of K562 and K562-CX3CR1 cells remaining bound to immo-
bilized chemokine-SEAP fusion proteins at 10 dynes/cm2. Error bars
represent the mean 6 SD. Data are representative of three experiments
performed.1418 Fractalkine Mediates Leukocyte Capture and Firm Adhesion
Further, the mouse homologue of FKN, neurotactin, is ex-
pressed at low levels on brain endothelium in normal mice
and upregulated on endothelium in inflamed brain in aller-
gic encephalomyelitis (10), suggesting that the FKN path-
way may be functional in leukocyte trafficking to inflamed
brain. Although trafficking of lymphocytes to brain during
peak inflammation in Sindbis virus–infected mice was
blocked by antibodies to the b2 integrin LFA-1, lympho-
cyte entry into the brain during the early inflammatory re-
sponse was not affected by antibodies to b1 integrins,
VLA-4, or CD44 (28), indicating that the lymphocytes mi-
grating to brain during early Sindbis virus infection used a
different pathway of leukocyte migration. It is intriguing to
hypothesize that the FKN pathway of circulating leukocyte
adhesion to endothelium may play an important role in the
accumulation of leukocytes on the endothelium of inflamed
brain, facilitating subsequent diapedesis and migration.
In summary, we have shown that FKN can capture cir-
culating leukocytes and induce their firm adhesion and ac-
tivation. Furthermore, FKN-mediated firm adhesion is de-
pendent on neither chemokine receptor signaling nor on
integrins or other cell adhesion molecules, suggesting an al-
ternate and novel regulatory mechanism for leukocyte traf-
ficking. This novel FKN-mediated pathway may be partic-
ularly relevant for the recruitment of monocytes, CD81 T
cells, and NK cells to sites of inflammation.
Figure 5. Expression of FKN
by TNF-activated HUVECs
and their ability to support arrest
of K562-CX3CR1 cells under
flow conditions. FKN expression
on HUVECs, either resting (A)
or stimulated with 100 ng/ml
TNF-a for 12 h (B), was mea-
sured by IF staining with mAb
1D6. Shown are histograms of
the reactivity of anti-FKN (1D6)
and control (P3) mAbs. Cells
were also counterstained with
anti-CD31-PE to ensure they
were endothelial cells. FKN was
expressed on a subset of CD311
TNF-activated HUVECs. (C)
Comparison of the level of FKN
expression by TNF-activated
HUVECs and ECV-FKN cells.
Shown are histograms of the re-
activity of mAb 1D6 with 12-h
TNF-activated HUVECs and
ECV-FKN cells. (D) K562-
CX3CR1 cells bind to TNF-
activated HUVECs but not to
resting HUVECs. K562-neo cells
and K562-CX3CR1 cells were
perfused over HUVECs and
TNF-activated HUVEC mono-
layers for 5 min at 0.5 dynes/
cm2, and subjected to a wall
shear stress of 1.85 dynes/cm2.
Shown are the numbers of firmly adherent cells to HUVECs and TNF-activated HUVECs at 1.85 dynes/cm2. Error bars represent the mean 6 SD. (E)
K562-CX3CR1 cells bind firmly to TNF-activated HUVECs at high wall shear stresses. K562-neo cells and K562-CX3CR1 cells were perfused over
TNF-activated HUVECs monolayers for 5 min at 0.5 dynes/cm2 and were subjected to increasing wall shear stresses up to 20 dynes/cm2. Shown are the
numbers of firmly adherent cells to TNF-activated HUVECs at various shear stresses from a representative experiment. All data are representative of at
least three independent experiments.
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